REFRaME|O1

The study that is redefining FRα-positivity in platinum-resistant ovarian cancer[1,2]

Previous studies of FRα-targeted therapy have failed to capture a majority of patients with FRα-expression[2,3]

80% of platinum-resistant ovarian cancer patients are potentially eligible for REFRaME-O1[1,3,4]

The REFRaME-O1 study aims to expand the definition of actionable FRα-expression, extending the opportunity for targeted therapy to more patients[1]

Folate receptor alpha (FRα) is a validated target that is overexpressed in ovarian cancer compared with normal tissue.[3,4] The REFRaME-O1 study in platinum-resistant ovarian cancer is part of the REFRaME trial program, which seeks to reframe our understanding of actionable FRα expression across a range of tumor types.

See reverse side for REFRaME-O1 eligibility requirements and study details

SUTRO BIOPHARMA

REFRaME|O1

A Phase II study of luveltamab tazevibulin in platinum-resistant ovarian cancer, a next-generation ADC developed using XpressCF+® cell-free technology[1]

BROAD FRα-EXPRESSION

COHORT A (N=25)

Cycles 1-2: luveltamab tazevibulin 5.2 mg/kg IV Q3W with prophylactic pegfilgrastim

Thereafter: luveltamab tazevibulin 4.3 mg/kg IV Q3W

COHORT B (N=25)

All cycles: luveltamab tazevibulin 4.3 mg/kg IV Q3W

INTERIM ANALYSIS*
Dosing regimen selected

CONTINUED THERAPY
Subjects continue on optimized dosing regimen, and ~100 patients added to study

*After ≥25 subjects in each cohort complete 2 or more cycles of luveltamab tazevibulin, a dosing regimen will be selected, and eligible subjects will have an opportunity to continue therapy through study completion.

Q3W=every 3 weeks.

Open for enrollment | Global study with 40+ locations

Trial design to support accelerated approval

Primary Endpoint	• Objective response rate
Secondary Endpoint	• Duration of response
Key Eligibility Criteria	• FRα-selected, relapsed platinum-resistant epithelial ovarian cancer • 1-3 prior regimens • Prior treatment with an FRα-targeted ADC or an ADC that contains a tubulin inhibitor is not permitted

Email Sutro at REFRaME@sutrobio.com, or visit sutrobio.com by scanning the QR code to learn more

References: 1. Data on file. Sutro Biopharma, Inc. **2.** Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. *J Clin Oncol*. 2023;41(13):2436-2445. **3.** Birrer MJ, Betella I, Martin LP, Moore KN. Is targeting the folate receptor in ovarian cancer coming of age? *Oncologist*. 2019;24(4):425-429. **4.** Bax HJ, Chauhan J, Stavraka C, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. *Br J Cancer*. 2023;128(2):342-353.

SUTRO BIOPHARMA